 - Any immunomodulatory or immunosuppressive therapy at any time prior to enrollment, including, but not limited to, the following products: any IFN, glatiramer acetate Copolymer I, cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment e.g. natalizumab, alemtuzumabCampath, anti-cluster of differentiation 4 CD4, intravenous, immunoglobulins Igs, cytokines or anti-cytokine therapy 